ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

NC-Approved Clinical Trials

June 27, 2003

NCI, NIH Make Half-Hearted Pitch For Cancer Act Before Seemingly Uninterested Rogers Committee

March 10, 1978

Immune System Booster Shown Safe For Prostate Cancer; Fewer Side Effects

August 29, 2008

Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals

September 25, 1998

In Brief: Cancer Panel to Meet Sept. 30 In Boston; House Passes Money Bill, With 41.347 Billion For NCI

August 15, 1986